Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis

@article{Hoerauf2008FilariasisND,
  title={Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis},
  author={Achim Hoerauf},
  journal={Current Opinion in Infectious Diseases},
  year={2008},
  volume={21},
  pages={673–681}
}
  • A. Hoerauf
  • Published 1 December 2008
  • Medicine
  • Current Opinion in Infectious Diseases
Purpose of review Chemotherapy against onchocerciasis and lymphatic filariasis has been discussed mainly within the framework of mass drug administration with diethylcarbamazine, ivermectin and albendazole. Although strong reductions in infection prevalence were achieved, the regimes for these drugs do not fully cover needs of individual patients who seek treatment because of symptoms. Chemotherapy against filarial Wolbachia endosymbionts with doxycycline showed higher antiparasitic efficacy in… 

Chemotherapy of filariasis – established strategies and new developments

TLDR
Current treatment options and current research approaches for optimization of anti-helminthic therapy are summarized and reviewed, including the exploration of optimized delivery strategies of ivermectin and albendazole, the discovery and development of new antibiotics for antiwolbachial chemotherapy and macrofilaricidal antihelminethics.

Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis

TLDR
Within a collaboration of the non-profit organizations Drugs for Neglected Diseases initiative (DNDi), the Bill & Melinda Gates Foundation, and partners from academia and industry, several new promising macrofilaricidal drug candidates were identified, which will be discussed in this review.

The Case for Doxycycline in Our Battle against Filariasis

TLDR
This scoping review argues that doxycycline is by far the most promising of the current anti wolbachial drugs under investigation and is relatively safe and does not generate adverse effects associated with rapid killing of worms as with some MDA drugs.

Elimination of lymphatic filariasis: do we have the drugs to complete the job?

TLDR
Alternative and effective MDA regimens and strategies will be needed if the GPELF is to achieve the goals of global elimination of lymphatic filariasis by 2020.

Macrofilaricidal activity and amelioration of lymphatic pathology in bancroftian filariasis after 3 weeks of doxycycline followed by single-dose diethylcarbamazine.

TLDR
The beneficial effects of doxycycline on lymphatic dilation is confirmed and adds to the existing evidence that doxy cycline, in addition to being macrofilaricidal, may be used to prevent or reverse lymphatic pathology.

Doxycycline depletes Wolbachia and kills adult worms of Wuchereria bancrofti

TLDR
This scoping review argues that doxycycline is by far the most promising of the current anti wolbachial drugs under investigation and is relatively safe and does not generate adverse effects associated with rapid killing of worms as with some MDA drugs.

New insights into the biology of filarial infections

TLDR
Questions such as the impact of filarial immunosuppression, and its lack following filarial control, on the outcome of co-infections were addressed, as were new approaches to treatment with promising drugs such as moxidectin or the antibiotic chemotherapy against Wolbachia endosymbionts in filariae.

Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus

TLDR
Doxycycline cannot replace regular ivermectin mass treatment because new infections would require repeated rounds of doxycycline, but it can be used for the treatment of individuals outside transmission areas, in foci where iver mectin resistance may occur, and in countries where onchocerciasis and loiasis are co-endemic.
...

References

SHOWING 1-10 OF 76 REFERENCES

Antibiotic therapy in murine filariasis (Litomosoides sigmodontis): comparative effects of doxycycline and rifampicin on Wolbachia and filarial viability

TLDR
The combination of antirickettsial drugs could be used as a suitable tool to explore the minimum duration of therapy required for the depletion of Wolbachia in parasitized hosts subsequent to the onset of patency in human and animal filariasis and the prevention of adverse reactions in human infections.

Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus

TLDR
Doxycycline cannot replace regular ivermectin mass treatment because new infections would require repeated rounds of doxycycline, but it can be used for the treatment of individuals outside transmission areas, in foci where iver mectin resistance may occur, and in countries where onchocerciasis and loiasis are co-endemic.

Strategies and tools for the control/elimination of lymphatic filariasis.

TLDR
New approaches to disease control, based on preventing bacterial superinfection, can now halt or even reverse the lymphoedema and elephantiasis sequelae of filarial infection.

The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole.

TLDR
The combination of ivermectin with albendazole given one week apart is well tolerated but produces no additional effect against Onchocerca volvulus when compared to iver mectin given alone.

Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment.

  • T. SupaliY. Djuardi E. Sartono
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
TLDR
A 6-week course of doxycycline, either alone or in combination with diethylcarbamazine-albendazole, leads to a decrease in microfilaremia and reduces adverse reactions to antifilarial treatment in B. malayi-infected persons.

Albendazole for lymphatic filariasis.

TLDR
There is insufficient evidence to confirm or refute that albendazole co-administered with DEC or ivermectin is more effective than DEC oriver mectin alone in clearing microfilariae or killing adult worms.

Doxycycline Reduces Plasma VEGF-C/sVEGFR-3 and Improves Pathology in Lymphatic Filariasis

TLDR
A 6-wk regimen of antifilarial treatment with doxycycline against W. bancrofti showed a strong macrofilaricidal activity and reduction in plasma levels of VEGF-C/sVEGFR-3, the latter being associated with amelioration of supratesticular dilated lymphatic vessels and with an improvement of pathology in lymphatic filariasis patients.
...